Menu
Intended for US HCPs Only

CoPay Assistance Program

Timmy, Actual FEIBA Patient

Do your patients need help paying for FEIBA?
WE’VE GOT YOU COVERED

Shire’s CoPay Assistance Program offers financial assistance to eligible patients.

If your patients qualify, they may:

  • Save up to $12,000 in out-of-pocket medication costs over over a 12 month period on FEIBA [Anti-Inhibitor Coagulant Complex]*
  • Receive reimbursement for their portion of their medication costs

Your patients may be eligible for CoPay assistance if:

  • They are starting or receiving FEIBA for hemophilia A or B with inhibitors
  • They have commercial insurance that covers medication costs for FEIBA and allows for CoPay or coinsurance assistance

How Patients Sign Up

It’s easy for patients to sign up for CoPay Assistance for FEIBA. They can call 1-888-BAX-8379 (1-888-229-8379) Mon–Fri, 8:30 AM to 8:00 PM ET and answer a few simple questions about themselves and their pharmacy. Shire handles the rest.

Patients can learn more information about the CoPay Assistance Program here.

*Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible. †Must have a current prescription for FEIBA with an ICD9 or ICD10, as applicable, of a hemophilia A or B inhibitor.

‡Not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law.

Click here for full terms and conditions

FREEDOM OF CHOICE Trial Program

Your patients may be eligible to receive 15 free trial doses of FEIBA.

See Details

Shire Programs

Access a variety of programs for your patients living with hemophilia regardless of treatment.

See Our Programs

Please expand for Indications and Detailed Important Risk Information

Selected Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: THROMBOEMBOLIC EVENTS

Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.

FEIBA [Anti-Inhibitor Coagulant Complex] Indications and Detailed Important Risk Information for Healthcare Professionals

Indications for FEIBA [Anti-Inhibitor Coagulant Complex]

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.

Detailed Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: THROMBOEMBOLIC EVENTS

The use of FEIBA is contraindicated in patients with:

Thromboembolic events (including venous thrombosis, pulmonary embolism, myocardial infarction, and stroke) can occur with FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.

Infusion of FEIBA should not exceed a dose of 100 units per kg body weight every 6 hours and daily doses of 200 units per kg body weight. Maximum injection or infusion rate must not exceed 2 units per kg of body weight per minute. Monitor patients receiving more than 100 units per kg of body weight of FEIBA for the development of DIC, acute coronary ischemia and signs and symptoms of other thromboembolic events. If clinical signs or symptoms occur, such as chest pain or pressure, shortness of breath, altered consciousness, vision, or speech, limb or abdomen swelling and/or pain, discontinue the infusion and initiate appropriate diagnostic and therapeutic measures.

Hypersensitivity and allergic reactions, including severe anaphylactoid reactions, can occur following the infusion of FEIBA. The symptoms include urticaria, angioedema, gastrointestinal manifestations, bronchospasm, and hypotension. These reactions can be severe and systemic (e.g., anaphylaxis with urticaria and angioedema, bronchospasm, and circulatory shock). Other infusion reactions, such as chills, pyrexia, and hypertension have also been reported. If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of FEIBA and provide appropriate supportive care.

Because FEIBA is made from human plasma it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most frequently reported adverse reactions observed in >5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.

The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.

Use of antifibrinolytics within approximately 6 to 12 hours after the administration of FEIBA is not recommended.

Please see FEIBA full Prescribing Information